香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 佈 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 SILVER GRANT INTERNATIONAL HOLDINGS GROUP LIMITED (於香港註冊成立之有限公司) 銀建國際控股集團有限公司 （股份代號：171） 截 至2025年12月31日止年度 年度業績公佈 銀 建 國 際 控 股 集 團 有 限 公 司（「本公司」或「銀 建」，連 同 其 附 屬 公 司，統 稱 為「本 集 團」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 集 團 截 至2025年12月31日止年度 （「2025年 度」）之 綜 合 業 績 如 下： – 1 – 綜合損益表 截 至2025年12月31日止年度 | 2025年 | 2024年 | 附 | 註 | 千港元 | 千港元 | | | | | | | | | | | | --- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Suzhou Novosense Microelectronics Co., Ltd. 蘇州納芯微電子股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2676） 截 至2025年12月31日止年度之 全年業績公告 本集團的財務摘要 本集團截至2025年12月31日止年度之綜合年度業績連同截至2024年12月31日 止 年度之比較數字如下： 截 至12月31日止年度 年度業績 蘇 州 納 芯 微 電 子 股 份 有 限 公 司（「本公司」及 其 附 屬 公 司「本集團」）董 事 會（「董 事 會」）欣 然 公 佈 本 集 團 截 至2025年12月31日止年度之綜合年度業績，連同截至2024 年12月31日止年度的比較數字。 合 併 財 務 報 表 已 按 歷 史 成 本 基 準 編 製，惟 若 干 以 公 允 價 值 計 量 且 其 變 動 計 入 其 他 綜 合 收 益 的 金 ...

Financial Performance - Revenue for the year ended December 31, 2025, was RMB 556,925,000, a decrease of 4.3% from RMB 584,794,000 in 2024[3] - The annual loss attributable to shareholders was RMB 66,763,000, slightly improved from a loss of RMB 68,243,000 in 2024[3] - Gross profit increased to RMB 17,833,000, up from RMB 16,777,000 in the previous year, reflecting a gross margin improvement[4] - Total sales revenue for 2025 was RMB 556,925,000, a decrease of 4.8% from RMB 584,794,000 in 2024[21] - Revenue from China in 2025 was RMB 434,457,000, down 5.5% from RMB 459,869,000 in 2024[21] - The net loss for the year attributable to shareholders was RMB 66,763,000, compared to RMB 68,243,000 in 2024[29] - The company recorded a net loss attributable to shareholders of approximately RMB 66,763,000 for the year ending December 31, 2025, a slight improvement from RMB 68,243,000 in 2024[57] - The company reported a net loss of RMB 67,170,000 for the year ending December 31, 2025[81] Assets and Liabilities - Total assets decreased to RMB 1,179,725,000 from RMB 1,249,758,000, indicating a reduction of 5.6%[6] - Current liabilities exceeded current assets by RMB 276,435,000, raising concerns about liquidity[9] - Non-current liabilities increased significantly to RMB 116,067,000 from RMB 61,868,000, primarily due to an increase in loans[6] - The actual interest rate for secured bank loans was 3.6%, down from 4.4% in the previous year, while the rate for unsecured loans was 3.0%, slightly down from 3.1%[39] - The total amount of bank and other loans was RMB 527,464,000, of which RMB 477,643,000 were current bank loans, while cash and cash equivalents amounted to RMB 68,152,000[76] - The debt-to-asset ratio increased to 56.2% as of December 31, 2025, compared to 53.3% in 2024, primarily due to depreciation reducing fixed assets and improved turnover reducing inventory[62] Cash Flow and Financing - Cash and bank balances stood at RMB 68,152,000, compared to RMB 57,963,000 in 2024, showing an increase of 17.6%[5] - The operating cash flow for the year was negative, leading to a reclassification of non-current bank loans of RMB 128,961,000 to current liabilities[42] - Financing costs increased to RMB 16,593,000 in 2025 from RMB 10,514,000 in 2024, primarily due to a decrease in capitalized interest on qualifying assets[55] - The group has an uncommitted revolving bank financing amounting to RMB 409,000,000, of which approximately RMB 139,104,000 remains undrawn[12] - The board believes that the group will have sufficient financial resources to meet its financial obligations for the next twelve months based on cash flow forecasts and planned measures[77] Dividends and Shareholder Information - The company did not recommend a final dividend for the year ended December 31, 2025[3] - The company did not declare any interim dividends for the year, consistent with 2024[30] - The company’s directors and executives hold significant shares, including 135,000,000 foreign shares (39.30%) and 12,236,000 H shares (6.66%)[82] - Major shareholders include Hong Kong Newborn Venture Capital Limited with 39.30% of foreign shares (135 million shares) and Hong Kong Biochemical High-Tech Investment Limited with 19.65% (67.5 million shares)[87] Operational Highlights - The group has integrated production lines of its subsidiaries to streamline processes and reduce costs, and will continue to implement cost-reduction measures[12] - The group is actively monitoring and controlling administrative expenses and future capital expenditures to minimize cash outflows[12] - The group launched 11 R&D projects in 2025, applying for 11 new patents, including 8 invention patents and 3 utility model patents, focusing on green process improvements and pharmaceutical excipient development[47] - The Dalian factory's second-phase production line for special anhydride products has been operating well, with product quality recognized by customers and steady capacity increases[48] - The group aims to enhance technological innovation and product upgrades, focusing on green processes, pharmaceuticals, electronic chemicals, and new materials in future R&D efforts[49] Compliance and Governance - The company maintains compliance with the corporate governance code as per the Hong Kong Stock Exchange regulations[94] - The audit committee has been established and includes three independent non-executive directors as of December 31, 2025[98] - The board consists of both executive and non-executive directors, ensuring a diverse governance structure[100] - Independent non-executive directors have confirmed their independence in accordance with the listing rules[96] Future Outlook - The group plans to improve overall performance in 2026 as the second-phase capacity of the Dalian factory is gradually released and synergies in the supply chain become evident[43] - Future strategies include accelerating the launch of new products and expanding into new market areas and applications, leveraging R&D and manufacturing advantages[53] - The group believes it can continue to operate based on its ability to generate sufficient financing and operating cash flows, despite significant uncertainties[13]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 二零二五年度業績公告 中國中鐵股份有限公司（「本公司」或「公司」或「中國中鐵」）董事會（「董事會」）欣然宣佈本 公司及其子公司（「本集團」）截至2025年12月31日止經審計的年度業績。 1 公司信息 基本信息 | 股票名稱： | 中國中鐵（A股） | 中國中鐵（H股） | | --- | --- | --- | | 股票代碼： | 601390 | 390 | | 股票上市交易所： | 上海證券交易所 | 香港聯合交易所有限公司 | | 註冊地址： | 中國北京市豐台區南四環西路128號院1號樓918 | | | 郵政編碼： | 100070 | | | 網址： | www.crec.cn | | | 電子郵件： | ir@crec.cn | | 聯繫方式 | 姓名： | 馬永紅（董事會秘書） | 段銀華（證券事務代表） | | --- | --- | --- | | 地址： | 中國北京市海淀區復興 ...

Financial Performance - For the fiscal year ending December 31, 2025, BBSB International Limited reported total revenue of MYR 147,229,000, an increase of 10.4% from MYR 133,002,000 in the previous fiscal year[4] - The gross profit for the same period was MYR 29,769,000, representing a gross margin of approximately 20.2%, compared to MYR 25,664,000 in the prior year[4] - The net profit attributable to shareholders for the fiscal year was MYR 6,289,000, a decrease of 76.0% from MYR 26,189,000 in the previous year[4] - Basic and diluted earnings per share for the fiscal year were MYR 1.68, down from MYR 6.98 in the previous year[4] - Other income for the current year totaled 2,447 thousand MYR, compared to 2,310 thousand MYR in the previous year, with interest income from short-term deposits at 172 thousand MYR[24] - The pre-tax profit before income tax for the current year was reported at 5,747 thousand MYR, a decrease from 7,084 thousand MYR in the previous year[26] - The net profit attributable to owners for FY2025 was approximately RM 6.3 million, down from RM 26.2 million in FY2024[63] Assets and Liabilities - Total assets as of December 31, 2025, amounted to MYR 125,505,000, an increase from MYR 109,044,000 in the previous year[5] - Current assets increased to MYR 113,213,000 from MYR 94,338,000, reflecting a growth of 20.0%[5] - Total liabilities rose to MYR 70,416,000, compared to MYR 55,244,000 in the previous year, indicating an increase of 27.5%[6] - The company's net asset value was MYR 55,089,000, up from MYR 53,800,000, showing a growth of 2.4%[6] - Trade receivables for 2025 amounted to 15,306 thousand MYR, down from 38,527 thousand MYR in 2024, with a provision for impairment of 732 thousand MYR[32] - The company reported a total of 26,368 thousand MYR in trade receivables and other receivables for 2025, compared to 38,258 thousand MYR in 2024[32] - The aging analysis of trade receivables showed that 8,368 thousand MYR was current, while 6,207 thousand MYR was overdue within one year for 2025[34] - The company had a significant concentration risk, with one customer accounting for 87% of total trade receivables in 2025, compared to two customers accounting for 71% in 2024[33] - Contract assets increased to 75,294 thousand MYR in 2025 from 32,928 thousand MYR in 2024, with a significant increase due to progress measurement changes and contract modifications[36] - The expected credit loss for contract assets was reported at 20,213 thousand MYR as of December 31, 2025[36] - Contract liabilities increased from 2,562 thousand MYR in 2024 to 3,838 thousand MYR in 2025[37] - Trade payables rose from 42,052 thousand MYR in 2024 to 52,592 thousand MYR in 2025, with third-party payables increasing from 24,997 thousand MYR to 32,313 thousand MYR[37] Operational Strategy - The company plans to continue expanding its civil engineering services in Malaysia, focusing on strategic investments and potential acquisitions to enhance market presence[8] - BBSB International Limited is committed to adopting new technologies and improving operational efficiencies to drive future growth[8] - The group aims to actively seek new project opportunities to supplement and solidify its order book while adhering to a prudent approach to navigate global uncertainties[51] - The group managed 5 ongoing projects with a total estimated contract value of approximately 723.5 million MYR as of December 31, 2025[50] Corporate Governance and Compliance - The group’s financial statements are prepared in accordance with International Financial Reporting Standards and the Hong Kong Companies Ordinance[16] - The group underwent a restructuring process, becoming the holding company of its subsidiaries as of December 22, 2025[13] - The audit committee was established on December 16, 2025, consisting of three independent non-executive directors, responsible for overseeing the financial reporting process and internal controls[85] - The company has complied with the corporate governance code as per GEM listing rules since the listing date[92] - The company has appointed a compliance advisor, and as of the announcement date, there are no interests that require disclosure under GEM listing rules[88] Shareholder Information - The major shareholder, BBSB Overseas, holds 75% of the issued shares, with 375,000,000 shares owned by Chen Zhenyuan[77] - The company declared an interim dividend of 1.43 MYR per share for 2025, totaling 5,000 thousand MYR, compared to 0.43 MYR and 1,500 thousand MYR for 2024[8] - The board declared an interim dividend of MYR 5.0 million for the fiscal year 2025, with no recommendation for a final dividend for the same fiscal year[90] - The company will hold its annual general meeting on June 30, 2026, with a notice to be published in accordance with GEM listing rules[96] - Share transfer registration will be suspended from June 25, 2026, to June 30, 2026[97] - All shareholder forms and related shares must be submitted by June 24, 2026, at 4:30 PM[97] Market Outlook - The Malaysian transportation infrastructure construction market is expected to maintain moderate growth in 2026, driven by government focus on enhancing national infrastructure[51]

釋義 除文義另有所指外，本公告所用詞彙應與本公告「釋義」章節所界定者具有相同涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 （ 於 中 華 人 民 共 和 國 註 冊 成 立 之 股 份 有 限 公 司 ， 中 文 公 司 名 稱 為華 泰 證 券 股 份 有 限 公 司 ， 在 香 港 以HTSC名 義 開 展 業 務 （股份代號：6886） 截 至 2025 年 1 2 月 3 1 日止年度之業績公告 董事會謹此宣佈本公司及其附屬公司截至2025年12月31日止年度之經審計業績。本公告 列載本公司2025年年度業績公告全文，並符合《香港上市規則》中有關年度業績初步公告 附載的資料之要求。 刊登年度業績公告及年度報告 本公司2025年年度業績公告將分別在香港聯交所網站(www.hkexnews.hk)及本公司網站 (www.htsc.com.cn)上刊發。 本公司2025年年度報告將於2026年4月30日或之前分別在香港聯交所及本公司網站上刊 ...

Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 1,165,673, a decrease of 9.3% compared to RMB 1,285,031 in 2024[3] - Gross profit for the same period was RMB 760,204, reflecting a decline of 20.3% from RMB 953,508 in 2024[3] - Loss attributable to equity holders of the parent company was RMB 675,460, an increase of 143.6% from RMB 277,234 in 2024[3] - The company reported a pre-tax loss of RMB 766,557, compared to RMB 290,718 in the previous year[4] - Other income and gains for the year ended December 31, 2025, totaled RMB 29,737,000, a decrease of 9.6% from RMB 32,847,000 in 2024[38] - The current income tax expense for the year ended December 31, 2025, was RMB 12,003,000, a decrease of 35.4% from RMB 18,555,000 in 2024[42] - The group did not recommend any dividend payment for the year ended December 31, 2025, consistent with 2024[45] - The company reported a net loss of RMB 743.7 million for 2025, an increase of RMB 465.3 million from a loss of RMB 278.4 million in 2024, primarily due to impairment provisions related to certain R&D projects[122] Assets and Liabilities - Total non-current assets decreased to RMB 4,501,550 from RMB 4,926,924 in 2024[7] - Current assets totaled RMB 2,042,923, down from RMB 2,387,397 in 2024[7] - Total liabilities increased slightly to RMB 3,092,944 from RMB 3,090,268 in 2024[7] - As of December 31, 2025, the net current liabilities amounted to RMB 1,050,021,000, an increase from RMB 702,871,000 in 2024[8] - Total assets minus current liabilities were recorded at RMB 3,451,529,000, down from RMB 4,224,053,000 in 2024[8] - The total non-current liabilities decreased to RMB 515,020,000 from RMB 612,945,000 in the previous year[8] - The company's equity attributable to owners of the parent was RMB 2,759,191,000, a decline from RMB 3,365,520,000 in 2024[8] Research and Development - The company incurred research and development expenses of RMB 191,275, down from RMB 363,126 in 2024[4] - The company operates five validated human vaccine technology platforms and has four wholly-owned vaccine production enterprises[54] - The company has 20 vaccine products in development across 12 disease areas, with 24 clinical approvals and 24 ongoing clinical trials, including 7 innovative vaccines in Class 1[55] - The company is actively advancing the development of its vaccine product pipeline through continuous technological innovation[75] Market and Sales - Vaccine sales accounted for RMB 1,165,662 in 2025, down from RMB 1,261,446 in 2024, representing a decline of 7.6%[35] - Revenue from mainland China was RMB 1,165,298 in 2025, compared to RMB 1,278,217 in 2024, indicating a decrease of 8.8%[32] - Revenue from other countries/regions dropped to RMB 375 in 2025 from RMB 6,814 in 2024, a decline of 94.5%[32] - The company has commercialized eight vaccine products targeting six disease areas, with recombinant hepatitis B vaccine and freeze-dried rabies vaccine being key products in the market[62] Inventory and Receivables - The company's inventory balance as of December 31, 2025, was RMB 347.4 million, a decrease of RMB 115.2 million or 24.9% from RMB 462.6 million as of December 31, 2024, primarily due to improved inventory management and provisions for near-expiry vaccines[125] - Trade receivables rose to RMB 1,241,722,000 in 2025 from RMB 1,173,906,000 in 2024, with a net trade receivable balance of RMB 1,197,595,000 after impairment[48] - The impairment loss for trade receivables decreased to RMB 44,127,000 in 2025 from RMB 51,153,000 in 2024[50] Financial Management - The company has successfully renewed bank loans amounting to RMB 134,620,000 and secured new bank loans of RMB 176,232,000 after December 31, 2025[14] - Cash and cash equivalents decreased to RMB 342,578 from RMB 494,265 in 2024[7] - The company's financing costs for 2025 were RMB 57.8 million, a decrease of RMB 3.0 million or 4.9% from RMB 60.8 million in 2024, primarily due to reduced bank loan balances and interest rates[120] Regulatory and Compliance - The group has adopted the revised International Accounting Standard No. 21 regarding the lack of exchangeability for the first time in the current financial statements[20] - The group plans to apply new and amended International Financial Reporting Standards when they become effective[21] - The company is committed to adhering to Good Manufacturing Practices (GMP) to ensure quality assurance in its production processes[152] Strategic Initiatives - The company is focused on expanding its market presence and exploring new strategies for growth[149] - The company plans to leverage its 20-year sales network and brand reputation to facilitate the market entry of new products, including the serum-free rabies vaccine[106] - The company aims to deepen cooperation with "Belt and Road" countries to address unmet medical needs globally[107] Employee and Corporate Governance - As of December 31, 2025, the company expects to have approximately 1,466 employees, increasing to about 1,535 by December 31, 2024[137] - Total employee benefit expenses, including director remuneration, are projected to be RMB 344.5 million for 2025, down from RMB 356.9 million in 2024[137] - The audit committee, consisting of three independent non-executive directors, has reviewed the financial results for the year ending December 31, 2025[143]

Financial Performance - Total operating revenue for the year ended December 31, 2025, was RMB 124,927,594 thousand, an increase of 5.8% from RMB 118,132,916 thousand in 2024[4] - Insurance service income reached RMB 103,087,051 thousand, up from RMB 101,363,282 thousand, reflecting a growth of 1.7% year-over-year[4] - Investment income significantly increased to RMB 12,084,972 thousand, compared to RMB 6,831,989 thousand in 2024, marking a growth of 77.5%[4] - Net profit for the year was RMB 10,217,271 thousand, a decrease of 7.8% from RMB 11,080,440 thousand in 2024[5] - Basic earnings per share for 2025 was RMB 0.23, down from RMB 0.25 in 2024[4] - The total comprehensive income for the year was RMB 8,579,546,000, which includes other comprehensive income losses of RMB 1,191,597,000[10] - Cash generated from operating activities for 2025 was RMB 22,629,103,000, up from RMB 11,930,645,000 in 2024, indicating a growth of approximately 89.8%[10] - The net profit for the year ended December 31, 2025, was RMB 9,771,143,000, representing a significant increase compared to the previous year's profit of RMB 10,556,993,000[10] Assets and Liabilities - Total assets as of December 31, 2025, amounted to RMB 527,763,431 thousand, an increase from RMB 508,347,105 thousand in 2024[6] - Total liabilities increased to RMB 408,448,737 thousand from RMB 395,682,308 thousand, reflecting a growth of 3.9%[7] - The total equity attributable to shareholders increased to RMB 109,644,587 thousand from RMB 103,255,661 thousand, representing a growth of 6.5%[7] - The company's cash and cash equivalents rose to RMB 16,623,145 thousand, compared to RMB 13,005,875 thousand in 2024, indicating a growth of 28.5%[6] Dividends and Shareholder Returns - The company paid dividends to shareholders amounting to RMB 2,123,990,000 in 2025, compared to RMB 1,784,152,000 in 2024, reflecting a 19% increase[11] - The proposed final dividend for the year ending December 31, 2025, is RMB 0.0691 per share, totaling approximately RMB 2.935 billion, subject to shareholder approval[190] - The proposed final dividend represents 30.19% of the consolidated net profit attributable to the parent company under Chinese accounting standards, aligning with the company's dividend policy[193] Segment Performance - The property reinsurance segment generated RMB 51,612,053 in revenue, accounting for a significant portion of the total income[23] - The group operates through various segments, including property reinsurance, life reinsurance, and asset management, to diversify its revenue streams[22] - The life reinsurance segment's insurance service revenue from protection-type reinsurance accounted for 95.2% of total revenue in 2025, showing a slight decrease of 0.8% from 2024[100] - The overseas property reinsurance business reported premium income of RMB 4.52 billion, a year-on-year increase of 5.4%, with insurance service revenue of RMB 3.43 billion, up 3.1%[73] Investment Performance - The company reported a total of RMB 357,697,859,000 from the sale of investment assets in 2025, compared to RMB 282,799,112,000 in 2024, indicating a growth of approximately 26.4%[10] - Total investment income for 2025 reached RMB 18.249 billion, a year-on-year increase of 4.9%[39] - Net investment income for 2025 was RMB 14.452 billion, reflecting a year-on-year growth of 1.4%[146] - The return on total investment for 2025 was 4.66%, down from 4.83% in 2024[145] Risk Management and Compliance - The company has adopted the Corporate Governance Code and complied with all applicable provisions during the reporting period[185] - The risk management framework was enhanced to ensure effective transmission of strategic asset allocation and risk appetite, with no major risk events reported during the year[139] - The group emphasizes the importance of compliance management and risk control systems to ensure sustainable growth[165] Market Trends and Strategic Initiatives - The reinsurance market is undergoing a deep transformation, requiring adaptation to market changes and the development of core competitiveness for sustainable high-quality growth[161] - The health insurance market is experiencing a strong demand for savings-type products, with a focus on innovative medical insurance products and health management services[163] - The company aims to enhance its digital solutions and improve underwriting capabilities through increased investment in product innovation[87] - The group plans to deepen product innovation and improve risk pricing and service enhancement as part of its high-quality development strategy[164]

（於開曼群島註冊成立的有限公司） （前稱 WMCH GLOBAL INVESTMENT LIMITED ） （股份代號：8208） 截 至 二 零 二 五 年 十 二 月 三 十 一 日 止 年 度 之 全 年 業 績 公 告 香 港 聯 合 交 易 所 有 限 公 司（「聯 交 所」）GEM之 特 色 GEM的 定 位，乃 為 相 比 起 其 他 在 聯 交 所 上 市 之 公 司 帶 有 較 高 投 資 風 險 之 中 小 型 公 司 提 供 一 個 上 市 之 市 場。有 意 投 資 者 應 了 解 投 資 該 等 公 司 之 潛 在 風 險，並 應 經 過 審 慎 周 詳 之 考 慮 後 方 作 出 投 資 決 定。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SHENZHEN ZHAOWEI MACHINERY & ELECTRONICS CO., LTD. 深圳市兆威機電股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2692） 截 至2025年12月31日止年度 業績公告 深 圳 市 兆 威 機 電 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司，統 稱「本集團」）董 事 會（「董事會」）謹 此 公 佈，本 集 團 截 至2025年12月31日 止 年 度（「報告期間」）合 併 全 年業績，連同截至2024年12月31日止年度比較數字如下： 財務摘要 截 至12月31日止年度 | | | | | 2025年 | 2024年 | 變 動 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 人民幣百萬元 | ...